CONTENTS
Special issue | Yearbook 2019
In association with
Christensella: the key to unlocking gut microbiome-based drug discovery?
How will the recall of API valsartan impact patients and the industry?
Why has the stock of pink Migraleve tablets disappeared from UK shelves?
Amanda Feilding'smost urgent policy issues yet to be addressed in the UK
The EMA is lowering the flag of its London base and moving to the Netherlands
Seperating the fact from fiction surrounding pharmaceutical CBD
The case for and against establishing a nationalised drug company in the UK
Research suggests that cancer cells can communicate further that we thought
Patients in the UK are banding together to access a costly cystic fibrosis treatment
Pharma is starting to move away from animal testing in favour of alternative options
Researchers have found a way to improve stability when attaching drugs to antibodies